An investigational compound for chronic plaque psoriasis has shown to be safe and effective. In an industry-sponsored phase III trial, the calcineurin inhibitor ISA247 significantly reduced the extent of psoriasis, compared with placebo.

Sponsored by The Doctor's Channel